A Selective Summary of Psychopharmacology Research Published in Second Half of 2015


Ahuja S, Bose A, Lu K, Greenberg W, Nemeth G, Laszlovszky I . A multicenter, randomized, double blind trial to evaluate the effect of cariprazine in bipolar depression. Poster presented at the Autumn Conference of the International Society for CNS Clinical Trials and Methodology; 2011. Amelia Island, Flack 3–4.

Durgam S, Earley W, Lipschitz A, Guo H, Laszlovszky I, Németh G, et al. An 8-week randomized, double blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J of Psychiatry 2015; Available from http://doi.org/10.1176/appi.ajp.2015.15020164.

Correll CU, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2015; 172(9):870–80.

Kane, JM, Skuban A, Ouyang, J, Hobart M, Pfister S, McQuade RD, et al. A multicentre, randomized, double blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res 2015; 164(1-3): 127–35.

Sinclair D, Adams CE. Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials. BMC Psychiatry [Internet]. 2014 Sep 12 [cited 2015 Dec 10];14. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177431/.

Berwaerts J, Liu Y, Gopal S, Nuamah I, Xu H, Savitz A et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry 2015; 72(8):830–39.

Carpenter WT, Buchanan RW, Kirkpatrick B, Lann HD, Breier AF, Summerfelt AT. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. Am J Psychiatry 1999; 156(3):412–18.

WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2015. Oslo: 2014.

Davis JM. Dose equivalence of the antipsychotic drugs. J Psychiatr Res 1974; 11:65–9.

Leucht S, Samara M, Heres S, Patel MX, Furukawa T, Ciprian A, et al. Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophr Bull 2015; 41(6):1397–402.

Jakubovski E, Varigonda AL, Freemantle N, Taylor MJ, Bloch MH. Systematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder. Am J Psychiatry 2015; Available from: http://doi.org/10.1176/appi.ajp.2015.15030331.

Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003; 60:1228–35.

Leucht S, Busch R, Hamann J, Kissling W, Kane JM. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 2005; 57:1543–9.

Samara MT, Leucht C, Leeflang MM, Anghelescu IG, Chung YC, Crespo-Facorro B, et al. Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry 2015; 172(7):617–29.

Sinclair D, Adams CE. Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials. BMC Psychiatry [Internet]. 2014 Sep 12 [cited 2015 Dec 10];14. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177431/

Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M. Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry 2015. Available from: http://doi.org/10.1176/appi.ajp.2015.15030332.

Miller AH, Raison CL. Are anti-inflammatory therapies viable treatments for psychiatric disorders? Where the rubber meets the road. JAMA Psychiatry 2015; 72(6):527–8.

Andrade, C. Anti-inflammatory strategies in the treatment of schizophrenia. Expert Rev Clin Pharmacol 2015; 1–3. Available from: http://doi.org/10.1586/17512433.2016.1095086.

Köhler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 2014; 71:1381–91.

Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013; 70(1):31-41.

Uher R, Tansey KE, Dew T, Maier W, Mors O,Hauser J, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry 2014; 171(12):1278-1286.

Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti, M, Carpenter W, Shergill S, et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull 2015; 41(4):892–9.

Gorwood P, Demyttenare K, Vaiva G, Corruble E, Llorca PM, Bayle F, et al. An increase in joy after two weeks is more specific of later antidepressant response than a decrease in sadness. J Affect Disord 2015; 185,97–103.

Geschwind N, Nicolson NA, Peeters F, van Os J, Barge-Schaapveld D, Wichers M. Early improvement in positive rather than negative emotion predicts remission from depression after pharmacotherapy. European Neuropsychopharmacol 2011; 21(3),241–7.